Entyvio is a gut-selective biologic therapy for moderate-to-severe Crohn’s disease that targets GI tract inflammation directly without suppressing the body’s entire immune system. In short, Targeted Mechanism: It binds to the alpha-4 beta-7 integrin protein, blocking inflammatory white blood cells from entering and damaging the digestive tract lining. Streamlined Treatment: Administered via a 30-minute IV
Read More
Footer
Medical Website Design and Medical Marketing by Hedy & Hopp.